Continuous Glucose Monitoring Use in Rural Area: An Evidence-Based Case Report
Abstract
Continuous Glucose Monitoring (CGM) provides real-time glycemic variability data, surpassing traditional methods like HbA1c. CGM data, also known as glucometrics, provide a comprehensive assessment of glycemic variability rather than a single point estimate like HbA1c, CGM data, or glucometrics. It provides a comprehensive assessment of glycemic variability rather than a single point estimate like HbA1c. CGM enables clinicians to understand dysglycemia patterns better by continuously tracking the patient's glucose levels, therefore allowing for individualized adjustments to antidiabetic therapy. By continuously tracking glucose levels, a CGM enables clinicians to understand dysglycemia patterns better, allowing for individualized adjustments to antidiabetic therapy. While costly, CGM enables long-distance monitoring, addressing healthcare inaccessibility in remote rural areas. This case reportstudy examines a 24-year-old Indonesian female patient diagnosed with young-onset diabetes with limited access to specialized care, a history of macrosomia at birth, high blood glucose, and a body mass index (BMI) of 27.7. The patient's abdominal circumference was 86 cm, which is above normal for women and within the range of obesity. In this patient, CGM recorded a mean glucose level of 145 mg/dL. Studies indicate that when at least 70% of CGM data is available over a 10-14-day period, an estimated HbA1c can be calculated. CGM is vital for diabetes management in rural settings.…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.